rs12444232 (GP2): Colorectal Cancer Risk Variant
Key takeaways
- rs12444232 is a GP2 gene variant examined in a colorectal cancer genome-wide association study.
- The study enrolled over 1,000 colorectal cancer cases and nearly 700 advanced colorectal polyp cases from an Austrian population.
- Two statistical methods were combined to detect genetic associations that standard single-marker analysis might miss.
- Specific association data for rs12444232 is not present in the available study excerpt, so effect size and significance cannot be reported here.
Key takeaways
- rs12444232 is a GP2 (glycoprotein 2) gene variant examined in a colorectal cancer genome-wide association study.
- The study enrolled over 1,000 colorectal cancer cases and nearly 700 advanced colorectal polyp cases from an Austrian population.
- Two statistical methods were combined to detect genetic associations that standard single-marker analysis might miss.
- Specific association data for rs12444232 is not present in the available study excerpt, so effect size and significance cannot be reported here.
What the research says An Austrian GWAS enrolled 1,060 colorectal cancer (CRC; a malignant tumor of the large intestine or rectum) cases, 689 advanced colorectal adenoma (a pre-cancerous polyp) cases, and 4,367 controls to identify genetic variants associated with disease risk. The study applied both conventional single-marker testing and model selection using mBIC2 - a modified Bayesian information criterion (a statistical measure for choosing among competing models) - specifically to recover variants whose associations fall below the standard genome-wide significance threshold of P < 5×10^-8 and might otherwise go undetected. A hypothesis-driven component also tested 56 SNPs with prior evidence of CRC susceptibility, of which several were confirmed relevant in the Austrian cohort; rs12444232 in the GP2 locus falls within this study context, though the provided text excerpt does not contain association statistics specific to this variant.
Reported associations
- Colorectal cancer risk: rs12444232 was evaluated in an Austrian CRC GWAS covering 1,060 cases and 4,367 controls; the available study excerpt does not report association statistics (odds ratio, p-value) for this specific variant.
- Advanced colorectal adenoma risk: The same study examined risk for advanced adenomas (689 cases) alongside CRC; variant-level results for rs12444232 are not present in the provided excerpt.
Evidence quality The source study represents a moderately sized European discovery cohort (1,060 CRC cases, 689 advanced adenoma cases, 4,367 controls) from an Austrian population. A dual analytical approach - single-marker testing combined with mBIC2 model selection - was designed to address the well-documented limitation that standard GWAS multiple-testing correction leaves a substantial proportion of truly associated SNPs undetected, contributing to what the authors describe as missing heritability. The study explicitly notes that identified CRC risk SNPs in European populations collectively explain only approximately 8% of familial CRC risk. Specific association data for rs12444232 - including p-value, effect size, and replication status - are absent from the provided text excerpt, making independent assessment of evidence quality for this variant impossible from the available information. The study authors note that all previously unreported SNPs identified by their approach require replication in additional samples.
Lifestyle considerations No lifestyle considerations on file for this variant.
Frequently asked questions
What is the GP2 gene?
GP2 (glycoprotein 2) is a gene whose variant rs12444232 was examined in a genome-wide association study focused on colorectal cancer and precancerous colorectal polyp risk. The available study text does not describe the biological function of GP2 in detail.
Is rs12444232 linked to colorectal cancer?
rs12444232 was included in an Austrian genome-wide association study of colorectal cancer and advanced adenoma risk. The available study excerpt does not report specific association statistics for this variant, so the strength or direction of any link cannot be stated from this source.
What is a genome-wide association study (GWAS)?
A GWAS scans hundreds of thousands of genetic variants across many people to find those statistically linked to a disease or trait. The study examining rs12444232 used both standard single-marker testing and a model-selection method called mBIC2 to improve the detection of risk variants that would otherwise fall below standard significance thresholds.
Why do some genetic risk variants go undetected in standard GWAS?
Standard GWAS applies very strict statistical thresholds to control false positives, which means variants with small but real effects are often missed. The study involving rs12444232 used model-selection techniques specifically designed to recover these sub-threshold associations, which may account for a portion of the missing heritability in colorectal cancer.
How large was the colorectal cancer study that examined rs12444232?
The Austrian study included 1,060 colorectal cancer cases, 689 advanced colorectal adenoma cases, and 4,367 controls, totaling more than 6,100 participants.